Contact
Please use this form to send email to PR contact of this press release:
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
TO:
Please use this form to send email to PR contact of this press release:
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
TO: